Stockscreener 앱 받기
5.69
6.95%
0.37
전일 마감가:
$5.32
열려 있는:
$5.33
하루 거래량:
44,897
Relative Volume:
0.59
시가총액:
$132.25M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.33%
1개월 성능:
-18.25%
6개월 성능:
-8.67%
1년 성능:
-33.45%
1일 변동 폭
$5.33
$5.84
1주일 범위
$5.08
$6.20
52주 변동 폭
$5.08
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
ACTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
5.69 | 123.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-26 | 개시 | B. Riley Securities | Buy |
| 2025-04-22 | 개시 | Craig Hallum | Buy |
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Analysis Recap: Is Actuate Therapeutics Inc stock undervalued right nowPrice Action & Risk Controlled Daily Plans - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Is Actuate Therapeutics Inc stock showing strong momentumPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Price Action: Is Actuate Therapeutics Inc stock risky to hold nowPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Quarterly Recap: Can Actuate Therapeutics Inc stock deliver consistent earnings growthJuly 2025 WrapUp & Smart Money Movement Tracker - Bộ Nội Vụ
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data - TipRanks
Actuate Therapeutics IncReports positive phase 2 trial data for elraglusibSEC filing - marketscreener.com
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Actuate Therapeutics Reports Positive Phase 2 Study Results for Elraglusib Combination in Metastatic Pancreatic Cancer - Quiver Quantitative
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at AS - GlobeNewswire
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Will Actuate Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analysts2025 Pullback Review & Weekly Return Optimization Alerts - Улправда
Can Actuate Therapeutics Inc. stock sustain market leadershipJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale - TipRanks
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares By Investing.com - Investing.com South Africa
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares - Investing.com Australia
Actuate Therapeutics Insider Sold Shares Worth $1,624,000, According to a Recent SEC Filing - marketscreener.com
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Canada
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results By Investing.com - Investing.com South Africa
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib - Quiver Quantitative
Experimental drug shrinks tough childhood tumors in early trial - Stock Titan
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
Winners Losers: Will Actuate Therapeutics Inc stock benefit from green energy trendsEarnings Miss & Real-Time Volume Analysis - Bộ Nội Vụ
Actuate Therapeutics, Inc. (ACTU) upgraded to buy: What does it mean for the stock? - MSN
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? - sharewise.com
Can Actuate Therapeutics Inc stock maintain growth trajectoryJuly 2025 Drop Watch & Consistent Income Trade Ideas - moha.gov.vn
Why Actuate Therapeutics Inc. stock remains on buy lists2025 Top Decliners & Real-Time Price Movement Reports - Улправда
What risks investors should watch in Actuate Therapeutics Inc. stockJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
How Actuate Therapeutics Inc. stock reacts to oil pricesJuly 2025 WrapUp & Daily Profit Focused Screening - DonanımHaber
How sustainable is Actuate Therapeutics Inc. stock dividend payoutBull Run & AI Forecasted Entry/Exit Points - DonanımHaber
Can Actuate Therapeutics Inc. stock maintain growth trajectory2025 Technical Patterns & Verified Technical Trade Signals - DonanımHaber
What Wall Street predicts for Actuate Therapeutics Inc. stock priceJuly 2025 Earnings & Low Volatility Stock Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI By Investing.com - Investing.com South Africa
Fed Meeting: Is Actuate Therapeutics Inc. stock a buy for dividend growthStop Loss & Free Community Consensus Stock Picks - Улправда
Is Actuate Therapeutics Inc. stock a buy for dividend growthQuarterly Trade Review & Consistent Income Trade Recommendations - Улправда
Actuate to present phase 2 pancreatic cancer study data at ASCO GI - Investing.com Nigeria
Actuate Therapeutics Announces Presentation of Phase 2 Study Data on Elraglusib in Metastatic Pancreatic Cancer at ASCO GI Cancers Symposium 2026 - Quiver Quantitative
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - The Manila Times
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer - GlobeNewswire
Actuate reports promising results for elraglusib in salivary cancer By Investing.com - Investing.com Australia
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):